### **USFDA**



Cliantha Research successfully concluded seven USFDA inspections in October - November for the late phase studies.

Date	Country	Location	Therapeutic Area	
11 Nov - 15 Nov	India	Pune	Neuropsychiatry	
11 Nov - 15 Nov	India	Vijaywada	Neuropsychiatry	
4 Nov - 8 Nov	India	Nashik	Dermatology	
4 Nov - 8 Nov	India	Pune	Neuropsychiatry	
4 Nov - 8 Nov	India	Hubali	Immunology	
21 Oct - 25 Oct	India	Mumbai	Dermatology	
14 Oct - 18 Oct	India	Kanpur	Orthopedics	

## **CAP**



Cliantha Research concluded a successful College of American Pathologists (CAP) inspection at the Delhi-NCR clinical lab on November 19th, 2019.

## **Bioanalytical Lab, India**

Bioanalytical Lab, Toronto completed the following new methods developed and validated.

Sr No	Molecule	Dose	LLOQ	Comment		
1	Ursodiol, Glycoursodeoxycholic acid and Tauroursodeoxycholic acid	2* 300 mg capsules, 2*250 mg/5 mL Suspension	0.1000 / 0.07000 / 0.002000 μg/mL	Simultaneous estimation of Ursodiol, Glycoursodeoxycholic acid and Tauroursodeoxycholic acid		
2	Furosemide	40 mg tablet	20.00 ng/mL	NA		
3	Moxifloxacin	400 mg tablet	0.025 μg/mL	NA		
4	Amioderone	200 mg tablet	3.000 ng/mL	NA		

### **Cliantha Team at ISCR**

Cliantha Team attended "2-Day Workshop on Research Manuscript Writing" conducted by Indian Society of Clinical Research held on 18th - 19th Oct 2019, at Novotel, Ahmedabad (India).



**Training Workshop** 

Full day offsite workshop was organised for QA/QC team of Ahmedabad and Vadodara India on 19th Oct 2019 at Adani Belvedere Club Ahmedabad. The workshop included learning through interactive sessions by the Training and QA teams, game plays, videos and skits.




# Read about the "Cliantha's Clinical Research Capabilities" at Chronicle Pharmabiz,

CPhIWW Edition.

**Cliantha Capabilities** 

Ms. Rashmi Pant (GM Marketing) from Cliantha contributed an article on "Future of Clinical Trials in Germany and impact of Brexit".

**Poster Presentation** 



for efficacy evaluation of reproxalap ophthalmic solution

National Conference on Pharmacovigilance, Ayush Suraksha on 9th - 10th November 2019 at Jamnagar.

Trial for Reproxalap

Mr. Nilesh Patel, from large molecule lab, presented a poster titled "Immunogenicity and approach to correlate immunological adverse events in case of Biosimilars" at

### N = 22N = 22N = 22Reproxetap 0.25% Reproxalap 0.5% Vehicle:



Cliantha Toronto Allergen Chamber Clinical

Three-way cross over clinical trial design



Cliantha Team at CPhI worldwide 2019 was represented by the 7 Member Expert team of Vijay Patel (CEO), Naveen Sharma (President), Anne Marie Salapatek (Chief

Scientific Officer), Dr. Chirag Shah (Sr Director Business Strategy, Late Phase), Rahul Nijhawan (Sr. Director, Early Phase), Abhishek Patel (GM, Business Development), Pedro Pedroso (Sr. Project Manager) at Booth 9H023 on

(5th - 7th Nov 2019)

### Cliantha team at ACAAI conference in Houston, TX (7th - 11th November) was represented by Cynthia O' Brien (Sr. Director Business Development) and Dr. Basma Ismail (R&D Scientist). Dr. Basma presented the poster on

Anjali Chudasama (Sr. Director - Business Development)

"Self-Reported Symptoms of Grass Allergic Subjects Correlate Positively with Symptom Scores Recorded In a Controlled Environment". Clinical Trials Innovation Programme (CTIP)

Cliantha team at Clinical Trial Innovation Programme (CTIP) conference in San Francisco, CA from 22-23 October

2019 was represented by Cynthia O' Brien (Sr. Director - Business Development) and